Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy
Saved in:
| Main Authors: | Yao Qi, Jia Wang, Jingyi Li, Qi Deng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2025-06-01
|
| Series: | Cancer Biology & Medicine |
| Online Access: | https://www.cancerbiomed.org/content/22/6/644 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
by: Crystal Mackall, et al.
Published: (2024-07-01) -
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
by: Frederick L. Locke, et al.
Published: (2025-06-01) -
Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
by: Yuan Tian, et al.
Published: (2025-02-01) -
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
by: Xuefeng Wang, et al.
Published: (2025-07-01) -
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
by: Andrew J. Portuguese, et al.
Published: (2025-03-01)